What conditions can GLP-1 medications treat
Katsurada K, Nakata M, Saito T, Zhang B, Maejima Y, Nandi SS, et al
Any references to metabolic, endocrine, or appetite-related pathways are provided strictly for scientific context within laboratory research and do not imply therapeutic, diagnostic, or clinical use
et al.) predicts a poor response to GLP-1 agonists precisely because the resistance lies downstream of both receptor classes
GLP-1 receptor agonists were initially developed to improve glycemic control in type 2 diabetes by enhancing insulin secretion and inhibiting glucagon release, with additional effects on appetite regulation and gastric emptying later recognized as clinically relevant (Chao et al
Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial